Tamper-Resistant PSE Takes Big Pharma Stage: Bayer Licenses Acura’s Formulation
This article was originally published in The Tan Sheet
Bayer gains exclusive worldwide license to Acura Pharmaceuticals’ Impede technology for use in a pseudoephedrine-containing product resistant to extraction to make methamphetamine. The deal is Acura’s first licensing, and the first move toward tamper-resistant PSE by a major pharma firm.
Register for our free email digests: